Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Engaging Peer Mentors for Opportunity, Well-Being, and Equity Realization-A Leadership Intervention for Women in Academic Medicine.

Journal of women's health (2002)·2025
Same author

Heplisav-B vs Standard Hepatitis B Vaccine Booster for Health Care Workers.

Annals of family medicine·2025
Same author

The PreQuine Platform: A novel diagnostic tool for measuring glucose-6-phosphate dehydrogenase (G6PD) activity and hemoglobin concentration.

PloS one·2024
Same author

Well-being at a Military Medical School and Implications for Military Retention.

Military medicine·2023
Same author

Guaiac-Based FOBTs vs. FITs for Colorectal Cancer Screening in Average-Risk Adults.

American family physician·2023
Same author

Blue Skies With Clouds: Envisioning the Future Ideal State and Identifying Ongoing Tensions in the UME-GME Transition.

Academic medicine : journal of the Association of American Medical Colleges·2022

Related Experiment Video

Updated: May 9, 2026

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
08:50

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Published on: January 9, 2026

Thrombocytosis: Rapid Evidence Review.

Pamela M Williams1, Alan L Williams2

  • 1Department of Family Medicine at the Uniformed Services University of the Health Sciences, Bethesda, Maryland.

American Family Physician
|May 8, 2026
PubMed
Summary
This summary is machine-generated.

Thrombocytosis, a high platelet count, is often secondary but can indicate essential thrombocythemia, a myeloproliferative neoplasm. Diagnosis involves genetic testing and risk stratification for managing thrombosis risk.

More Related Videos

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

A Comprehensive Approach to Analyze the Cell Components of Cerebral Blood Clots
06:12

A Comprehensive Approach to Analyze the Cell Components of Cerebral Blood Clots

Published on: July 21, 2023

Related Experiment Videos

Last Updated: May 9, 2026

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
08:50

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Published on: January 9, 2026

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

A Comprehensive Approach to Analyze the Cell Components of Cerebral Blood Clots
06:12

A Comprehensive Approach to Analyze the Cell Components of Cerebral Blood Clots

Published on: July 21, 2023

Area of Science:

  • Hematology
  • Oncology

Background:

  • Thrombocytosis is defined as a platelet count ≥ 450 × 103/μL.
  • While often secondary, persistent thrombocytosis may signal myeloproliferative neoplasms like essential thrombocythemia (ET).
  • ET presents with symptoms such as headaches, paresthesia, erythromelalgia, splenomegaly, thrombosis, or hemorrhage.

Purpose of the Study:

  • To outline the diagnostic approach for persistent thrombocytosis.
  • To detail the workup for suspected essential thrombocythemia.
  • To guide risk stratification and management of ET.

Main Methods:

  • Confirming thrombocytosis with repeat CBC and peripheral smear.
  • Performing JAK2, CALR, and MPN gene variant testing.
  • Utilizing the International Prognostic Score for Thrombosis (IPSET) for risk stratification.
  • Considering bone marrow biopsy if ET is suspected and genetic testing is negative.

Main Results:

  • Diagnostic workup includes genetic testing (JAK2, CALR, MPN) and risk assessment using the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET).
  • Management strategies involve addressing cardiovascular risk factors, low-dose aspirin, and cytoreductive therapy, with hydroxyurea as the first-line agent.
  • Current treatments do not improve survival or prevent progression to myelofibrosis or leukemia.

Conclusions:

  • Persistent thrombocytosis necessitates a thorough diagnostic evaluation to rule out myeloproliferative neoplasms.
  • Risk stratification using IPSET is crucial for guiding management decisions in essential thrombocythemia.
  • While treatments manage symptoms and thrombosis risk, they do not alter the long-term prognosis of ET.